PMID:12395317

Citation	Coutant, A, Rescan, C, Gilot, D, Loyer, P, Guguen-Guillouzo, C and Baffet, G (2002) PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival. Hepatology 36:1079-88
Abstract	Growth factors are known to favor both proliferation and survival of hepatocytes. In this work, we investigated the role of 2 main signaling pathways, phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK), in these processes. First, evidence was provided that the PI3K cascade as well as the MEK/ERK cascade is a key transduction pathway controlling hepatocyte proliferation, as ascertained by arrest of DNA synthesis in the presence of LY294002, a specific PI3K inhibitor. Inhibition of FRAP/mTOR by rapamycin also abrogated DNA replication and protein synthesis induced by growth factor. We showed that expression of cyclin D1 at messenger RNA (mRNA) and protein levels was regulated by this pathway. We highlighted that 4E-BP1 phosphorylation was not activated by epidermal growth factor (EGF) but was under an insulin-regulation mechanism through a PI3K-FRAP/mTOR activation that could account for the permissive role of insulin on hepatocyte proliferation. No interference between the MEK/ERK pathway and 4E-BP1 phosphorylation was detected, whereas p70S6K phosphorylation induced by EGF was under a U0126-sensitive regulation. Last, we established that the antiapoptotic function of EGF was dependent on MEK, whereas LY294002 and rapamycin had no direct effect on cell survival. Taken together, these data highlight the regulation and the role of 2 pathways that mediate growth-related response by acting onto distinct steps. In conclusion, hepatocyte progression in late G1 phase induced by EGF generates survival signals depending on MEK activation, whereas PI3K and MEK/ERK cascades are both necessary for hepatocyte replication.
Links	PubMed Online version:10.1053/jhep.2002.36160
Keywords	Animals; Carrier Proteins/metabolism; Cell Division/physiology; Cell Survival/physiology; Cells, Cultured; Cyclin D1/metabolism; DNA/biosynthesis; Enzyme Inhibitors/pharmacology; Epidermal Growth Factor/pharmacology; G1 Phase/physiology; Hepatocytes/cytology; Hepatocytes/enzymology; Insulin/metabolism; MAP Kinase Kinase Kinase 1; MAP Kinase Signaling System/drug effects; MAP Kinase Signaling System/physiology; Male; Mitogen-Activated Protein Kinases/metabolism; Phosphatidylinositol 3-Kinases/antagonists & inhibitors; Phosphatidylinositol 3-Kinases/metabolism; Phosphoproteins/metabolism; Phosphorylation; Protein Biosynthesis; Protein Kinases/metabolism; Protein-Serine-Threonine Kinases/metabolism; Proto-Oncogene Proteins/metabolism; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; S Phase/physiology; TOR Serine-Threonine Kinases
edit table

Annotations

Gene product	Qualifier	GO Term	Evidence Code	with/from	Aspect	Extension	Notes	Status
RAT:PK3CB	enables	GO:0035004: phosphatidylinositol 3-kinase activity	ECO:0000303: author statement without traceable support used in manual assertion		F		Seeded From UniProt	complete

References

See Help:References for how to manage references in GONUTS.